4.92
+0.065(+1.34%)
Currency In USD
| Previous Close | 4.85 |
| Open | 4.89 |
| Day High | 5.01 |
| Day Low | 4.85 |
| 52-Week High | 14.6 |
| 52-Week Low | 3.79 |
| Volume | 455,452 |
| Average Volume | 855,948 |
| Market Cap | 269.83M |
| PE | -7.45 |
| EPS | -0.66 |
| Moving Average 50 Days | 5.97 |
| Moving Average 200 Days | 6.44 |
| Change | 0.07 |
If you invested $1000 in Candel Therapeutics, Inc. (CADL) since IPO date, it would be worth $702.14 as of September 12, 2025 at a share price of $4.915. Whereas If you bought $1000 worth of Candel Therapeutics, Inc. (CADL) shares 3 years ago, it would be worth $1,310.67 as of September 12, 2025 at a share price of $4.915.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
GlobeNewswire Inc.
Sep 02, 2025 12:05 PM GMT
NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cance
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
GlobeNewswire Inc.
Aug 28, 2025 12:05 PM GMT
NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire Inc.
Jul 30, 2025 12:05 PM GMT
NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer